Evidence map›Paper›PMID 40183549›Full record

ArticleJournal of clinical microbiology2025

Establishment of epidemiological cutoff values for

Dallas J Smith, Marcia S C Melhem, Jessy Dirven, Conceição Maria Pedrozo E Silva de Azevedo, Sirlei Garcia Marques, Bruna Jacomel Favoreto de Souza Lima, Vania Aparecida Vicente, Maria da Glória Teixeira Sousa, James Venturini, Nathan P Wiederhold and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026
    Article
  3. Establishment of epidemiological cutoff values againstJournal of clinical microbiology · 2026
    Article
  4. Article
  5. Frontiers in microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Dallas J SmithMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-5707-528X
Marcia S C MelhemSchool of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, State of Mato Grosso do Sul, Brazil.
Jessy DirvenWesterdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.
Conceição Maria Pedrozo E Silva de AzevedoPost-graduation Program of Health Science, Federal University of Maranhao, São Luís, Maranhão, Brazil.
Sirlei Garcia MarquesLaboratório Cedro, São Luís, Maranhão, Brazil.
Bruna Jacomel Favoreto de Souza LimaPost-graduation Program of Microbiology, Parasitology and Pathology, Federal University of Parana, Curitiba, Brazil.
Vania Aparecida VicentePost-graduation Program of Microbiology, Parasitology and Pathology, Federal University of Parana, Curitiba, Brazil.
Maria da Glória Teixeira SousaFaculdade de Medicina FMUSP, Institute of Tropical Medicine, Universidade de Sao Paulo, São Paulo, State of São Paulo, Brazil.
James VenturiniSchool of Medicine, Federal University of Mato Grosso do Sul, Campo Grande, State of Mato Grosso do Sul, Brazil.
Nathan P WiederholdFungus Testing Laboratory, Department of Pathology and Laboratory Medicine, University of Texas Health Science Center, San Antonio, Texas, USA.ORCID 0000-0002-2225-5122
Amir SeyedmousaviMicrobiology Service, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
Philippe J DufresneLaboratoire de santé publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.
Sybren de HoogRadboudumc/CWZ Center of Expertise for Mycology, Nijmegen, The Netherlands.ORCID 0000-0002-5344-257X
Shawn R LockhartMycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-4383-5994
Ferry HagenWesterdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.ORCID 0000-0002-5622-1916
Daniel Wagner de C L SantosDepartment of Infectious Diseases and Infection Control, Universidade Federal do Maranhão, EBSERH, São Luís, Maranhão, Brazil.

Funding

Molecular Epidemiology of Clinically Important Fungi and Pathobiology of Fungal InfectionsZIACL090088 · CLC · CLINICAL CENTER · PI SEYEDMOUSAVI, AMIR · 2022 to 2025
$0k
Intramural NIH HHS ZIA CL090088
6 · The paper itself

Abstract

Chromoblastomycosis, a fungal neglected tropical disease, is acquired through traumatic inoculation and is clinically characterized by a chronic granulomatous infection of the skin and subcutaneous tissue.

Indexed as

Antifungal AgentsChromoblastomycosisFonsecaeaDrug Resistance, FungalHumansItraconazoleMicrobial Sensitivity TestsTerbinafineTriazolesVoriconazoleAntifungal AgentsItraconazoleposaconazoleTerbinafineTriazolesVoriconazolechromoblastomycosisepidemiological cutoff valueFonsecaea pedrosoifungiimplantation mycosisneglected tropical disease

Identifiers

PMID40183549
PMCPMC12077196

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.